<DOC>
	<DOCNO>NCT02431403</DOCNO>
	<brief_summary>Open-labeled , multicenter , phase I/II study imatinib combine ESHAP salvage therapy relapsed/refractory non-Hodgkin 's lymphoma</brief_summary>
	<brief_title>ESHAP-Imatinib Refractory/Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>1 . Histologically diagnosed nonHodgkin 's lymphoma , refractory relapse 1st line treatment . 2 . Paraffin block lesion available immunohistochemical analysis 3 . Candidate ESHAP salvage therapy 4 . Evidence least one lesion diameter 1.5 cm 5 . Age 20 year 6 . Eastern cooperative oncology group performance status ( ECOG ) less equal 2 . 7 . Adequate kidney function serum creatinine &lt; 2.5 mg/dL , creatinine clearance ≥ 50 mL/min 8 . Adequate liver function aspartate transaminase ( AST ) /alanine aminotransferase ( ALT ) low equal 3 time normal upper limit ; Total bilirubin low equal 1.5 time upper limit ; alkaline phosphatase lower equal 5 time normal upper limit . 9 . Adequate bone marrow function absolute neutrophil count ≥ 1,000/uL ; platelet ≥ 75,000/uL ; hemoglobin ≥ 9.0 g/dL 10 . Patients give voluntarily inform consent perform test test part routine care patient 1 . Patients history exposure imatinib BcrAbl tyrosinekinase inhibitor 2 . Known suspected hypersensitivity imatinib 3 . Potential use usage alteration CYP3A4 inducer inhibitor prior 21 day test regimen initiation round 2 ESHAP . Exceptions itraconazole fluconazole treatment prevention fungal infection , hydrocortisone dexamethasone treatment nausea/vomiting/fluid retention , methylprednisolone part ESHAP regimen . 4 . Known involvement central nervous system ( CNS ) lymphoma . 5 . Pregnant breastfeeding . Females childbearing potential agree undergo pregnancy test repeat use effective birth control include clinical trial . 6 . Serious uncontrolled medical condition , presence abnormal clinically significant cardiac disease , acute myocardial infarction unstable angina within 6 month prior initiation treatment ESHAPimatinib , serious neurological psychological condition dementia epilepsy , uncontrolled active infection . 7 . Prior history malignancy nonHodgkin 's lymphoma ( except basal squamous cell skin situ carcinoma cervix ) unless patient free disease beyond 5 year . 8 . HIV positive treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>